Clinical trials located in

Strakonice

Strakonice city is located in Czechia. Currently, 7 clinical trials are being conducted in this city.

Strakonice, nestled in the South Bohemian Region of Czechia, is renowned for its rich history and cultural heritage. The city’s heart is dominated by the Strakonice Castle, a blend of Gothic and Renaissance architecture, which has stood since the 13th century. Strakonice is also famous for its traditional bagpipe music, hosting an international bagpipe festival that celebrates this unique aspect of its cultural identity. The Otava River, which flows through the city, adds to its picturesque charm, while the local brewery, founded in 1649, continues to produce beer using centuries-old recipes.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    • GSK3511294 (Depemokimab)
  • Advancing asthma management: study evaluates triple therapy inhaler

    This Phase 3 study evaluates the PT010 inhaler, a combination of budesonide, glycopyrronium, and formoterol, in adults and adolescents with inadequately controlled asthma. The study compares PT010 to standard treatments, assessing its effectiveness in improving lung function and reducing asthma exacerbations. Approximately, 2200 participants will be enrolled and monitored over 24 to 52 weeks. The trial aims to improve asthma management and quality of life for those with persistent symptoms despite current treatments.

    • Formoterol Fumarate
    • Glycopyrronium
    • Budesonide
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Czechia:

.